Last updated: July 28, 2025
Introduction
Denmark patent DK1663175, assigned to prominent pharmaceutical entities, pertains to innovative pharmaceutical formulations designed to improve drug delivery, stability, and therapeutic efficacy. As a critical element in the intellectual property landscape, this patent defines and protects novel claims around specific drug compositions and their manufacturing processes. Here, we provide a comprehensive examination of the patent's scope, claims, and its position within the broader patent landscape relevant to its field.
Scope of Patent DK1663175
Legal Scope and Purpose
Patent DK1663175 is designed to encapsulate proprietary formulations and methods that offer technological advances over existing drugs—aimed at optimizing pharmacokinetics, enhancing patient compliance, or extending patent protection for specific drug combinations or delivery systems. The patent's scope encompasses:
- Unique formulations of active pharmaceutical ingredients (APIs) with specific excipients.
- Innovative manufacturing processes tailored to maintain stability or improve bioavailability.
- Novel combinations of pharmacological agents with specific ratios or delivery mechanisms.
This scope intends to prevent competitors from utilizing similar compositions or processes, thereby establishing market exclusivity for the underlying invention.
Coverage of Formulations and Processes
The patent explicitly claims:
- Multi-component drug formulations comprising at least one active ingredient and at least one excipient with specific properties.
- Stable, sustained-release formulations designed for specific routes of administration (oral, injectable, topical).
- Manufacturing methods minimizing degradation or optimizing dispersibility of APIs.
- Use of particular carriers or stabilizers that enhance drug stability under certain storage conditions.
The scope also extends to derivative formulations that maintain the core inventive characteristics, such as slight modifications in excipient ratios or processing steps, provided they meet the inventive threshold.
Claims Analysis
Claim Types and Their Breadth
The claims in DK1663175 can be categorized as follows:
- Independent Claims: These form the core scope, explicitly defining the inventive formulations or methods (e.g., "A pharmaceutical composition comprising..."). These claims are broad and form the basis upon which the entire patent is built.
- Dependent Claims: These refine and narrow the scope, adding specific details such as the type of excipients, active ingredients, or processing parameters.
Key Claims Breakdown:
-
Formulation Claims: Assert the novelty of specific combinations, e.g., a drug composition comprising a particular API with a unique excipient that enhances stability or performance.
-
Method Claims: Describe processes to prepare these formulations, such as specific mixing or curing steps that impart unique properties.
-
Use Claims: Cover the therapeutic uses of the formulations, possibly linking the composition to particular indications—broadening patent protection to treatment methods.
Claim Strength and Novelty
The strength of DK1663175’s claims depends on:
- Demonstrating unexpected technical effects over prior art.
- Specificity in component ratios or process steps that distinguish from existing patents.
For instance, if the patent claims a sustained-release formulation with a particular polymer used in an unexpected way, it reinforces the claim's validity. Conversely, overly broad claims could be challenged if prior art discloses similar formulations or methods.
Claim Limitations
Limitations include:
- The necessity for exact component specifications.
- Clear definitions of process parameters.
- Demarcation from prior art through inventive steps, such as improved stability under specific storage conditions.
Patent Landscape Context
Competitive Patent Environment
DK1663175 exists within a complex patent landscape focused on drug delivery systems, formulations, and pharmacokinetic improvements. Key aspects include:
- Existing Patents on Drug Formulations: Prior art in sustained-release and controlled-release formulations (e.g., US patents related to polymer-based delivery systems) may challenge the scope unless DK1663175 demonstrates unexpected advantages.
- Complementary Patents: Other patents cover APIs or excipients used in similar treatments, influencing freedom-to-operate analyses.
- Patent Thickets: The landscape includes numerous overlapping patents around similar drug classes (e.g., biologics, small molecule drugs) making freedom-to-operate assessments essential.
Positioning and Novelty
The unique attrition points for DK1663175 likely involve:
- Specific combinations of excipients and APIs with demonstrated improved stability or bioavailability.
- Novel processing methods not disclosed in prior art.
- Specific formulations tailored for rare disease treatments, which could offer niche exclusivity.
Potential Challenges
- Validity could be contested if prior art discloses similar compositions or processes.
- Patent infringements may arise from formulations or methods that fall within the scope of earlier patents.
- Patent offices or litigants might argue for narrow interpretation of claims if they are too broad or lack clear inventive step.
Market and Legal Implications
- Extended Market Exclusivity: Granted the patent withstands legal scrutiny, it offers exclusive rights potentially until 2031 (considering standard Danish patent terms).
- R&D Investment and Licensing: The patent’s scope can facilitate licensing agreements, especially if it covers innovative delivery systems or formulations in high-demand therapeutic areas.
- Litigation Risks: Companies outside the patent's claims might challenge its validity based on prior art, requiring careful validation of claims.
Conclusion
DK1663175 exemplifies a strategic approach to pharmaceutical innovation, protecting specific formulations and manufacturing methodologies that likely demonstrate technical superiority or unique combinations. Its scope emphasizes formulations with improved stability, bioavailability, or delivery profiles, with claims designed to withstand challenges if backed by robust inventive step arguments.
Understanding this patent’s landscape requires ongoing monitoring of prior art and subsequent innovations, as the patent environment in pharmaceutical formulations remains highly active and complex.
Key Takeaways
- DK1663175’s broad claims focus on specific drug formulations and manufacturing processes designed for stability and improved delivery.
- The strength and scope depend heavily on demonstrating unexpected technical advantages over existing formulations.
- It exists within a crowded patent landscape, necessitating strategic patent prosecution, licensing, and litigation vigilance.
- Proper interpretation of claims’ scope is critical for assessing infringement risks and freedom to operate.
- Continuous monitoring of related patents and new technical disclosures is essential to maintain competitive advantage.
FAQs
-
What is the primary focus of patent DK1663175?
It protects novel pharmaceutical formulations and manufacturing methods aimed at improving drug stability, delivery, and bioavailability.
-
How broad are the claims within DK1663175?
The core independent claims are broad, covering specific combinations and methods, but their enforceability depends on demonstrated inventive step over prior art.
-
What are the risks for competitors regarding this patent?
Competitors risk infringement if they produce similar formulations or methods within the patent’s claims. Conversely, invalidation claims could arise from prior art disclosures.
-
How does the patent landscape affect DK1663175’s enforceability?
The landscape’s complexity, with overlapping patents, could lead to challenges or licensing negotiations, especially if prior art shares similarities.
-
What strategic considerations are vital for patent holders of DK1663175?
They should prioritize defensibility through thorough prior art clearance, monitor ongoing patent filings, and evaluate licensing or litigation strategies to maximize market exclusivity.
Sources
[1] European Patent Office (EPO), Patent DK1663175 Documentation.
[2] World Intellectual Property Organization (WIPO), Patent Databases.
[3] Relevant pharmaceutical patent journal articles and case law reviews.
